GET DAILY SIGNALSDarioHealth (DRIO) Delivers Q3 Revenue Growth but Extends Breakeven Outlook to 2028
Key Takeaways
- Third quarter 2026 revenue rose 6% year over year to $5.3 million, marking a return to growth after a decline in the prior quarter.
- Net loss narrowed to $8.8 million from $10.5 million a year earlier, though the per-share loss came in modestly wider than consensus.
- Consumer (direct-to-consumer) revenue jumped roughly 48% and reached 53% of total revenue, while enterprise revenue softened as legacy contracts were not renewed.
- Management extended its breakeven timeline to 2028, with contracted annual recurring revenue (ARR) converting gradually through 2027 and into 2028.
- Gross margin slipped to 59.2%, and cash, cash equivalents and short-term deposits stood at $31.2 million at quarter-end.
Why This Quarter Matters for DarioHealth
DarioHealth runs an AI-powered digital health platform aimed at helping employers, health plans, and individuals manage conditions like diabetes, hypertension, and weight. This earnings release felt particularly important because the company has announced several sizable contract wins in recent quarters, including a Fortune 50 employer and multiple state health plans, yet those have not fully shown up in reported revenue. The third quarter offered an early look at whether the channel-partner approach could restart top-line expansion. With the stock trading well below its mid-2026 raise price, the market was focused on whether revenue momentum and narrower losses were beginning to line up.
The Reported Results
DarioHealth posted third-quarter 2026 revenue of $5.3 million, up 6% from $5.0 million a year earlier and up 3% sequentially from $5.2 million. The figure came in slightly above the consensus estimate of about $5.2 million. Consumer, or direct-to-consumer, revenue rose approximately 48% year over year and accounted for 53% of total revenue, versus 38% a year ago. Services and enterprise revenue declined as several legacy contracts were not renewed, though channel-partner growth provided some offset. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the digital health space.
Gross profit reached $3.1 million, producing a gross margin of 59.2%, down from 61.7% in the second quarter. Operating expenses fell 10% year over year to $11.2 million, and the operating loss improved 15% to $8.0 million. Net loss narrowed to $8.8 million from $10.5 million a year earlier; the per-share loss of roughly $0.73 came in modestly wider than the consensus near $0.68. Non-GAAP operating loss was $5.3 million. The company finished the quarter with $31.2 million in cash, cash equivalents, and short-term deposits.
Market Reaction and Sentiment
Investor reaction to the report was negative, and shares fell sharply in the following session. Attention seemed centered on the lengthened path to profitability rather than the return to revenue growth. Management’s confirmation that breakeven is now targeted for 2028, with contracted and late-stage ARR converting through 2027 and into 2028, tempered near-term optimism. Growth in the quarter came mostly from lower-margin consumer sales, while the higher-margin enterprise segment stayed soft. Sentiment ahead of the release had already been cautious amid questions about when large contract wins would translate into the income statement.
Forward Outlook and Items to Monitor
Looking ahead, the focus will be on whether DarioHealth can turn its signed pipeline into recognized revenue without additional delays. The company added a third state health plan through its Amwell channel partnership—a New Jersey arrangement covering roughly 1.5 million lives—along with other channel opportunities covering more than 100,000 and about 250,000 lives. Revenue from the New Jersey agreement is not expected until the second half of 2027, and roughly 40% of ARR stems from administrative services only agreements that tend to convert slowly.
Cost discipline remains a positive, with operating expenses down 10% year over year, yet sequentially higher stock-based compensation and a lower gross margin raise questions about whether the narrowing trend can continue. The DarioIQ AI engagement system, which now predicts member disengagement, was highlighted as a tool for lifting engagement-based revenue. Newer offerings such as Dario Women and Dario Sleep are also expected to add to results over time.
Key items to watch include the pace of ARR conversion, the revenue mix between higher-margin enterprise and lower-margin consumer business, cash burn relative to the $31.2 million balance, and any fresh channel partnerships. Management expressed comfort with 2027 consensus, but execution against that view will be the key test.
Using AI Tools in My Research Process
I often turn to Tickeron’s AI Screener when reviewing earnings releases like this one. The tool lets me filter stocks by technical patterns, fundamentals, and AI-driven signals across thousands of names, which helps me quickly compare DarioHealth with peers in digital health. It has become a practical part of how I prepare these updates and spot broader trends without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DRIO in -30.96% downward trend, declining for three consecutive days on November 12, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where DRIO declined for three days, in 281 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for DRIO entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
DRIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.422) is normal, around the industry mean (4.477). P/E Ratio (-0.160) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.386) is also within normal values, averaging (6.065).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. DRIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technology to address the diabetic self-monitoring of blood glucose
Industry ServicestotheHealthIndustry
Advertisement